Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide.
Sixteen dogs with a histologic diagnosis of hemangiosarcoma were treated with surgery and doxorubicin/cyclophosphamide. The patients' characteristics, ie, age, size, and breed, were similar to those of previous studies. Historic controls for surgery alone were used to evaluate efficacy of the chemotherapy. The results show a trend of improved survival in dogs with localized disease (Stage I) receiving combination therapy. The median survival was 250 days, with a mean of 403 days. The survival times for dogs with stage I, II, and III disease was also improved with combination therapy, when compared to historical controls treated with surgery alone. The overall median survival was 202 days with a mean of 285 days. Toxicities included mild to moderate neutropenia (9 of 16) and clinical signs, such as lethargy, anorexia, vomiting, diarrhea, and fever (13 of 16). Three dogs had severe neutropenia requiring hospitalization and supportive care. One dog died from sepsis and related complications. Chemotherapy with doxorubicin and cyclophosphamide appears to improve survival with acceptable morbidity in patients with early stage disease.
Sorenmo
K U
KU
Department of Clinical Studies, University of Pennsylvania, School of Veterinary Medicine, Philadelphia.
Jeglum
K A
KA
Helfand
S C
SC
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000662:veterinary; D003520:Cyclophosphamide / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule / Q000662:veterinary; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D004317:Doxorubicin; D003520:Cyclophosphamide